Teva Pharmaceuticals Says Generic Version Of Forteo Approved In U.S

RTTNews | il y a 525
Stocktwits
Teva Pharmaceuticals Says Generic Version Of Forteo Approved In U.S

(RTTNews) - Teva Pharmaceuticals Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced Friday the approval of a generic version of Forteo in the United States. Forteo had annual sales of $609 million as of July 2023, according to IQVIA data.

Teva's generic equivalent of Forteo (teriparatide injection) utilizes the Antares Pharma, Inc. multi-dose pen device. Teriparatide injection is indicated to treat osteoporosis among certain women and men.

The market availability of the drug-device combination product in the U.S. is expected in the coming weeks.

Antares, a wholly owned subsidiary of Halozyme Therapeutics, Inc., and Teva are parties to an exclusive license, development and supply agreement for Teriparatide auto injector product that Teva markets in the EU and will market in the U.S.

Tags: TEVA
Stocktwits
read more
UroGen Pharma Files Patent Infringement Lawsuit Against Teva Pharma

UroGen Pharma Files Patent Infringement Lawsuit Against Teva Pharma

Biotech company UroGen Pharma Ltd. (URGN) announced Wednesday that it has filed a lawsuit in the U.S. District Court for the District of Delaware against Teva Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., and Teva Pharmaceutical Industries, Ltd. (TEVA), alleging infringement of U.S. Patent Numbers 9,040,074 and 9,950,069.
RTTNews | il y a 387
Teva Pharma Boosts FY23 Revenue Outlook - Update

Teva Pharma Boosts FY23 Revenue Outlook - Update

While reporting financial results for the third quarter on Wednesday, Teva Pharmaceutical Industries Ltd (TEVA) reaffirmed its adjusted earnings guidance for the full-year 2023, while raising annual revenue outlook.
RTTNews | il y a 534
Teva Pharma Boosts FY23 Revenue Outlook - Update

Teva Pharma Boosts FY23 Revenue Outlook - Update

While reporting financial results for the second quarter on Wednesday, Teva Pharmaceutical Industries Ltd (TEVA) reaffirmed its adjusted earnings guidance for the full-year 2023, while raising annual revenue outlook.
RTTNews | il y a 632
Teva Pharma Reaffirms FY23 Outlook - Update

Teva Pharma Reaffirms FY23 Outlook - Update

While reporting financial results for the first quarter on Wednesday, Teva Pharmaceutical Industries Ltd (TEVA) reaffirmed its adjusted earnings and revenue guidance for the full-year 2023.
RTTNews | il y a 716
Teva Recalls FENTANYL Buccal Tablets CII

Teva Recalls FENTANYL Buccal Tablets CII

Teva Pharmaceuticals USA is recalling specific lots of various strengths of FENTANYL Buccal Tablets CII to the consumer level citing a labeling error, the U.S. Food and Drug Administration said. The recall has been initiated because safety updates were omitted in the product insert/medication guide that are provided with these recalled lots.
RTTNews | il y a 725
Teva Pharmaceutical Appoints Eric Hughes As Chief Medical Officer

Teva Pharmaceutical Appoints Eric Hughes As Chief Medical Officer

Teva Pharmaceutical Industries Ltd. (TEVA) announced Friday the appointment of Dr. Eric Hughes, MD, PhD as Executive Vice President, Global R&D and Chief Medical Officer. Hughes will begin his employment on August 1, 2022, and will be based out of Teva's U.S. headquarters in Parsippany, New Jersey.
RTTNews | il y a 1029
Outils
Calendrier Économique
Market Hours
Interest Rates
Holidays Calendar
Marchés Forex
Volatilité Forex
Corrélation Forex
Actualités du Forex
forex analysis
Données COT
Liquidité
Calculatrices Forex
Heat Map du Forex
Indicators Heatmap
Communauté
Communauté
Systèmes
Systèmes les plus populaires
Stratégies
Concours
Graphiques Forex
Sentiment Forex
Indicateur de perspectives
Revues
Courtiers
Prop Trading Firms
Services SPV
Fournisseur de signaux
Services de programmation EA
Affiliate Programs
Services de courtage PAMM
Remise de services de programme
Plateformes de trading
Conseillers Experts
Marchés de crypto-monnaies
Trading Courses
Courtiers
Spreads de Forex
Cotations de courtiers Forex
Swaps de courtiers Forex
Volume du courtier Forex
Promotions des courtiers Forex Press Release
Plateforme
Widgets
Fonctionnalités
API
RSS
Stock Portfolio
Affiliate Software
Graphiques avancés
Support
FAQ
Aide
Contactez-nous
Signaler un bug!
À propos de
Blog
&copier; 2025 Myfxbook Ltd. Tous droits réservés.
AVERTISSEMENT SUR LE RISQUE ÉLEVÉ : Le trading de devises comporte un niveau de risque élevé qui peut ne pas convenir à tous les investisseurs. Leffet de levier crée un risque supplémentaire et une exposition aux pertes. Avant de décider de négocier des devises, examinez attentivement vos objectifs dinvestissement, votre niveau dexpérience et votre tolérance au risque. Vous pourriez perdre une partie ou la totalité de votre investissement initial. Ninvestissez pas largent que vous ne pouvez pas vous permettre de perdre. Renseignez-vous sur les risques associés au trading de devises et demandez conseil à un conseiller financier ou fiscal indépendant si vous avez des questions. Toutes les données et informations sont fournies "en létat", uniquement à titre dinformation, et ne sont pas destinées à des fins de trading ou de recommandation. Les performances passées ne sont pas indicatives des résultats futurs.